Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 13/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
| ▸ | LHCGR | P22888 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24906485 | 0.92 | AKR1C3 (0.38) | AKR1C3AKR1C2BACE1BACE2EPHX2 | |
| SCHEMBL30107035 | 0.92 | AKR1C3 (0.38) | AKR1C3AKR1C2BACE1BACE2EPHX2 | |
| SCHEMBL24757336 | 0.87 | AKR1C3 (0.37) | AKR1C3AKR1C2BACE1BACE2 | |
| SCHEMBL24906299 | 0.86 | SCN10A (0.42) | AKR1C3AKR1C2 | |
| SCHEMBL30107028 | 0.82 | NR3C1 (0.38) | AKR1C3AKR1C2BACE1BACE2 | |
| SCHEMBL24758290 | 0.82 | NR3C1 (0.38) | AKR1C3AKR1C2BACE1BACE2 | |
| SCHEMBL24758208 | 0.80 | AKR1C3 (0.39) | AKR1C3AKR1C2BACE1BACE2 | |
| SCHEMBL24757816 | 0.80 | NR3C1 (0.40) | AKR1C3AKR1C2BACE1BACE2 | |
| SCHEMBL24906534 | 0.80 | HTR2A (0.35) | AKR1C3AKR1C2BACE1CYP1A2CYP3A4 | |
| SCHEMBL30107015 | 0.80 | HTR2A (0.35) | AKR1C3AKR1C2BACE1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | GRUENENTHAL GMBH (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2022263498-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025025-A1 | SUBSTITUTED PYRAZOLE AMIDES | SCN8A, SCN1A, SCN7A | AKR1C3 1950/4885AKR1C2 1995/4885BACE1 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.